Enhanced support for the development of promising new medicines: PRIME one year on

Industry experience: Case study 2 – Aducanumab for Alzheimer's Disease

Simon Bennett – Director, Regulatory Policy, Biogen Limited

14 July 2017, BIA/MHRA Annual Conference

Opinions expressed are solely my own and are not the views or opinions of Biogen

Background

Aducanumab for Alzheimer's Disease

- **Alzheimer's Disease (AD) is a continuum,**
  - extending from preclinical disease, with evidence of changes in the brain and/or biomarkers but no clinical symptoms, to early symptomatic phases (e.g., MCI due to AD), and ultimately dementia.
  - AD is the most common cause of dementia, accounting for 50% to 75% of all cases.
- **Aducanumab – an investigational monoclonal antibody for patients with AD**
  - Two global phase 3 studies in subjects with early AD.
  - Potential benefit of PRIME is the added value that inclusion in the scheme can bring over other EMA tools such as scientific advice (life span discussion and post-authorisation evidence generation).



PRIME: Enhanced support

An important role

Concept

- Strengthened regulatory toolkit
- Early identification of therapeutic innovation
- Quicker access to treatment
- Faster development of promising medicines

Eligibility

- Demonstrate potential to address unmet medical need
- Major public health interest
- No satisfactory method of diagnosis, prevention or treatment
- Potential major therapeutic advantage



Expected Benefits

- Enhanced regulatory and scientific support
- Early rapporteur assignment
- EMA kick-off meeting – rapporteur, SAWP, EMA
- Scientific advice at key milestones
- Multi-stakeholder engagement
- Confirm potential accelerated assessment

PRIME: Enhanced support

Summary of progress to-date



- Potential submission of Aducanumab into the PRIME scheme was first considered by the company in 2015
- EMA launched PRIME in early March 2016
  - European Commission commented that PRIME is a major step forward for patients and their families for unmet medical needs, such as rare cancers, Alzheimer's disease and other dementias.
  - CHMP/SAWP agreed that there is a clear unmet medical need in Alzheimer's disease and that Aducanumab has the potential to significantly address this unmet need

PRIME: Enhanced support

Kick-off meeting preparation

Briefing package

- Tailored to key topics for future engagement
- Substantial background provided
- Tabulated assessment outlining stakeholders to be involved and initial timelines

Pre-meeting Preparation

Dedicated EMA support/ contact

Multidisciplinary approach to meeting - success of an accelerated process depends on all aspects of a development program

Agenda

- Structured with specific points raised by the Rapporteur for consideration
- Facilitated development of focussed slide deck
- Scientific questions out of scope – to be covered in scientific advice

PRIME: Enhanced support

Kick-off meeting discussion and outcomes

Kick-off meeting with EMA, Rapporteur, CHMP/SAWP Chairs September 2016

Rapporteur assessment team fully prepared and engaged

Context for discussion and feedback was to facilitate a smooth regulatory pathway

EMA proposed to utilise shorter lead in time to centralised advice (40 days rather than 70)

Role of centralised EMA advice; significant value in multi-stakeholder scientific advice

Post authorisation strategy key element of discussion

Reassurance around unanswered questions to be addressed

Further discussion between EMA and patient advocacy groups to ensure best involvement.

PRIME: Enhanced support

One year of experience

- **Guidance on application and kick-off meeting clear and relatively straightforward to follow;**
  - the briefing package for the kick-off meeting - on the one hand the guidance advises a short and focused package but the list of topics to cover in the annex is very long and requires substantial detail.

- **Periodic update meetings with EMA/Rapporteur to check-in on progress and any changes in the development of each product – especially important when earlier in development and engagement may be less frequent.**

PRIME: Enhanced support

One year of experience

- **Rapporteurs discuss the development program with the applicant and identify which areas/concerns should be raised to centralised advice**
  - However, important to also maintain the option of informal discussions on an ongoing basis.
  - Allowing for workload, ensures close engagement during development and could be a key attribute of the PRIME scheme.

- **Although centralised advice is preferred by the EMA, national SA can continue to be sought but may not always be possible**
  - This should be made clear to potential applicants if this is the case.
  - We believe it is important that national expertise in specific areas be included in future engagement, including that which has been previously sought.

PRIME: Enhanced support

Looking forward

Multi-stakeholder advice is critical

- While the mechanism for multi-stakeholder advice already exists in Europe, the ability to bring these groups together with the Rapporteur, earlier in development is a critical component of the PRIME scheme



PRIME: Enhanced support

Looking forward

Potential for accelerated assessment

- Reduces the review time within the centralised procedure for medicines designated by EMA to be of major public interest or a therapeutic innovation – saving ~ 4-6 months
- While this is an existing mechanism, early Rapporteur assignment allows continual dialogue to ensure that the development strategy continues to support a package acceptable for an accelerated procedure.
- The opportunity for centralised advice within PRIME means that CHMP and the Rapporteur are engaged from an earlier stage, which increases the likelihood of keeping to an accelerated timetable.



PRIME: Enhanced support

Conclusions after one year

We support initiatives that facilitate multi-stakeholder engagement.

It is important to ensure scientific rigour to meet all stakeholders needs

- patients, regulators and HTABs
- With the ultimate aim of providing earlier access for innovative products that encompass robust data collection

PRIME is voluntary scheme

- Ensures early, coordinated and continuous partnering and interactions between stakeholders to optimise development plans and,
- has the potential to speed up evaluation so these medicines can reach patients earlier.

We are excited as a company to be part of the PRIME scheme. If we can support in shaping the scheme and help to make it a success, then this can only be good for patients, the regulatory system and for future medicines.

Thankyou for your attention